SYS-CON MEDIA Authors: Unitiv Blog, Kevin Benedict, Mark R. Hinkle, Glenn Rossman, Jason Bloomberg

News Feed Item

Health Canada: Note to Editors

OTTAWA, ONTARIO -- (Marketwired) -- 01/14/14 -- Health Canada today released the January 2014 issue of the Canadian Adverse Reaction Newsletter (CARN).

This issue includes an article on a class of cancer drugs known as VEGF receptor inhibitors, which are used to inhibit tumour cell growth, and the risk of a serious blood clotting disorder known as thrombotic microangiopathy (TMA).

It also includes an article on a potential increased risk of complications when Durepair Dura Regeneration Matrix, a collagen graft used for membrane repair in neurosurgery, is used with other products used to close or seal wounds.

The edition also contains a quarterly summary of health professional and consumer advisories.

The January 2014 edition of CARN is available on Health Canada's website at:

Media Inquiries:
Media Relations
Health Canada

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.